SLC5A2 and hydrops fetalis: In the future, involvement of the HF specialist team is likely to become ever more important for HFpEF patients as prognostic therapies beyond SGLT2 inhibitors emerge from clinical trials into practice guidelines19 and the focus of treatment during and after AHF hospitalisation extends beyond decongestion.